Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ODM-204
- Development stage
- Phase 2
- Lead developer
- Orion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ODM-204 is a novel, orally administered, nonsteroidal small molecule that acts as a dual inhibitor of both CYP17A1 (steroid 17-alpha-hydroxylase) and the androgen receptor. By inhibiting CYP17A1 in the testes and adrenal glands, ODM-204 suppresses androgen production, while direct antagonism of the androgen receptor blocks androgen signaling. This dual mechanism is designed to efficiently dampen androgenic stimuli that drive castration-resistant prostate cancer (CRPC). ODM-204 was developed by Orion for the treatment of metastatic castration-resistant prostate cancer but its development has been discontinued[1][2][4][5][6].
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)AR (Adrenergic receptors)
Beyond the preview
Go deeper on ODM-204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ODM-204.